Drugs / Isoproterenol
Regulatory milestones approvals, filings & regulatory actions · 3 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansions (2) | US (FDA) | ISUPREL | — | 1986-10-08 – 1999-05-04 | fda.gov ↗ |
| Approved | US (FDA) | ISUPREL | — | 1948-02-19 | fda.gov ↗ |
Trials 14
1946194719481949195019511952195319541955195619571958195919601961196219631964196519661967196819691970197119721973197419751976197719781979198019811982198319841985198619871988198919901991199219931994199519961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027202820292030203120322033
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 03 trials | ||||||
| Phase 0 | NCT06520982 | Sep 2024 → Jun 2027 expected | sympathetic nervous system disorder | University of Missouri-Columbia | Recruiting | No outcome recorded |
| Phase 0 | NCT05219799 | Mar 2023 → Jun 2026 overdue | isoproterenol-mediated vasodilatation, obesity disorder | University of Missouri-Columbia | Recruiting | No outcome recorded |
| Phase 0 | NCT06643221 | Jan 2018 → May 2031 expected | leukemia, lymphoma | University of Arizona | Recruiting | No outcome recorded |
| Phase 11 trial | ||||||
| Phase 1 | NCT02833207 | Apr 2012 → Nov 2021 | obesity disorder | University of Wisconsin, Madison | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00624416 | Oct 2007 → Mar 2009 | lipoma | Pennington Biomedical Research Center | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00323843 | Jun 2006 → Feb 2007 | urolithiasis | Fredericia Hosptial | Unknown | No outcome recorded |
| Phase 42 trials | ||||||
| Phase 4 | NCT05997732 | Oct 2023 → Dec 2027 expected | — | University of Alberta | Recruiting | No outcome recorded |
| Phase 4 | NCT05658692 | Oct 2022 → Oct 2023 | acute respiratory distress syndrome | Second Affiliated Hospital, School of Medicine, Zhejiang University | Unknown | No outcome recorded |
| Phase not applicable6 trials | ||||||
| — | NCT03019081 | Jan 2017 → Aug 2021 | anorexia nervosa | Laureate Institute for Brain Research, Inc. | Unknown | No outcome recorded |
| — | NCT02725060 | Feb 2016 → Oct 2026 expected | cardiac rhythm disease, postural orthostatic tachycardia syndrome, primary dysautonomia | Vanderbilt University Medical Center | Enrolling by invitation | No outcome recorded |
| — | NCT02615119 | Oct 2015 → Jun 2023 | anorexia nervosa, brain injury, generalized anxiety disorder, major depressive disorder +1 | Laureate Institute for Brain Research, Inc. | Completed | No outcome recorded |
| — | NCT02524145 | Jun 2015 → Nov 2017 | heart failure | University of Texas Southwestern Medical Center | Completed | No outcome recorded |
| — | NCT01377636 | Aug 2009 → Sep 2011 | — | NYU Langone Health | Completed | No outcome recorded |
| — | NCT00226551 | Aug 1999 → ? | coronary artery disorder | Hadassah Medical Organization | Completed | No outcome recorded |
| Comparator or background therapy7 trials | ||||||
| Phase 1 | NCT00748059 Background | Dec 1996 → Dec 2020 | autonomic nervous system disorder, disorder of catecholamine synthesis, orthostatic hypotension | Vanderbilt University Medical Center | Completed | No outcome recorded |
| Phase 2 | NCT03032965 Background | Oct 2011 → Jul 2015 | paroxysmal atrial fibrillation | University of Michigan | Completed | No outcome recorded |
| Phase 2/3 | NCT00428428 Comparator | Feb → Nov 2007 | benign urinary system neoplasm, urolithiasis | Fredericia Hosptial | Completed | No outcome recorded |
| — | NCT04950881 Background | Jul 2021 → Dec 2022 | — | Daping Hospital and the Research Institute of Surgery of the Third Military Medical University | Unknown | No outcome recorded |
| — | NCT04274413 Background | Feb 2021 | CFTR-related disorder, cystic fibrosis | The Hospital for Sick Children | Withdrawn | No outcome recorded Stop: Business |
| — | NCT02726620 Background | Jan → Dec 2017 | hypotensive disorder | Vanderbilt University Medical Center | Completed | No outcome recorded |
| — | NCT02310789 Background | Jul 2015 → Aug 2016 | cystic fibrosis | Richard Barry Moss | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 22 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Isoproterenol | “Lastly, beta-adrenergic sweating will be stimulated by injecting a combination of the following drugs: atropine, isoproterenol, and aminophylline (β-cocktail).” NCT04274413 ↗20“Agonists include: ATP, Bradykinin (BK), Isoproterenol (ISO), and Acetylcholine (Ach), will be infused 3 times each (order randomized).” NCT02833207 ↗ “atropine (0.01-0.02mg/kg) or isoproterenol (1-2 μg/per time)is given intravenously to increase the heart rate.” NCT04950881 ↗ “Cocktail composed of atropine (280µM), isoproterenol (160µM), and aminophylline (20 mM).” NCT02310789 ↗ “isoproterenol” NCT05658692 ↗ |
| Known as | Isoproterenol Hydrochloride | “Drug: Isoproterenol Hydrochloride” NCT05997732 ↗ |
| Action | Activate | “Isoproterenol is a direct acting Beta-1 and Beta-2 agonist useful for its effects on bronchodilation and myocardial contractility.” NCT01377636 ↗ |
| Modality | Small molecule | “synthetic β agonist (isoproterenol) infusion model” PMID 40311885 ↗ Apr 2025 |
| Route | Other | “endoluminally administrated isoproterenol” NCT00428428 ↗ |